Biotech · Public company · La Jolla, CA, US

Boundless Bio, Inc.

Ticker BOLD · SEC CIK 0001782303

Track this companyFree. Adds Boundless Bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

BBI-355Phase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
BBI-825Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
BBI-825Phase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
BBI-940Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ErlotinibPhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
FulvestrantPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
FutibatinibPhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerPHASE1 · TERMINATED · started Feb 25, 2026ClinicalTrials.gov NCT07408089 · fetched Nov 12, 2026
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene AmplificationsPHASE1 · TERMINATED · started Mar 28, 2024ClinicalTrials.gov NCT06299761 · fetched Nov 12, 2026
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsPHASE1 · TERMINATED · started Mar 24, 2023ClinicalTrials.gov NCT05827614 · fetched Nov 12, 2026